Overview

Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To clarify the potential benefits of NACT before radical surgery(RS), we perform a phase III, randomised controlled trial to compare NACT plus RS with RS alone in patients with stages IB2 and IIA2 cervical cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Carboplatin
Cisplatin
Paclitaxel